Related Experiment Video
Updated: Jul 11, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.0K
The Best Psoriasis Medications Emerge
Andrew Blauvelt1, Megan H Noe2
1Oregon Medical Research Center, Portland.
JAMA Dermatology
|November 15, 2023
Summary
Four systemic medications, including infliximab, bimekizumab, ixekizumab, and risankizumab, demonstrate similar effectiveness for treating plaque psoriasis. These drugs showed no significant increase in serious adverse events compared to placebo.
Area of Science:
- Dermatology
- Pharmacology
- Immunology
Background:
- Plaque psoriasis is a chronic autoimmune condition requiring effective systemic treatments.
- Identifying superior systemic therapies is crucial for improving patient outcomes.
- Comparative effectiveness research guides clinical decision-making.
Approach:
- A meta-analysis was conducted to compare the efficacy and safety of systemic medications for plaque psoriasis.
- Four specific drugs—infliximab, bimekizumab, ixekizumab, and risankizumab—were evaluated.
- Clinical effectiveness and serious adverse events were primary endpoints.
Key Points:
- Infliximab, bimekizumab, ixekizumab, and risankizumab were identified as the most effective systemic drugs for plaque psoriasis.
- The clinical effectiveness of these four agents was comparable.
- No statistically significant differences in serious adverse events were observed between these drugs and placebo.
Conclusions:
- These four systemic medications represent highly effective treatment options for plaque psoriasis.
- Current evidence suggests similar efficacy and safety profiles for infliximab, bimekizumab, ixekizumab, and risankizumab up to 52 weeks.
- Further research is needed to assess long-term effectiveness and non-serious adverse events.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
01:29Drugs for Treatment of Ulcerative Colitis in IBD
146
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
146
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
147
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
147
01:19Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324